[Significance of HDL cholesterol increase for the risk reduction. Methods of intervention. recommendations of experts].
D000214:Acyl Coenzyme A / Q000627:therapeutic use; D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000378:metabolism*; D002995:Clofibric Acid / Q000627:therapeutic use; D003327:Coronary Disease / Q000378:metabolism* / Q000517:prevention & control*; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D009525:Niacin / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D040242:Risk Reduction Behavior; D012955:Societies, Medical / Q000592:standards
D000214:Acyl Coenzyme A; D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; C008047:3-hydroxy-3-methylglutaryl-coenzyme A; D009525:Niacin; D002995:Clofibric Acid